Exhaled markers of inflammatory lung diseases: ready for routine monitoring?
Assessing airway inflammation is important for investigating the underlying mechanisms of many lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). Yet these are not measured directly in routine clinical practice because of the difficulties in monitoring inflammation. The presence and type of airway inflammation can be difficult to detect clinically, and may result in delays in initiating appropriate therapy. Non-invasive monitoring may assist in differential diagnosis of lung diseases, assessment of their severity and response to treatment. There is increasing evidence that breath analysis may have an important place in the diagnosis and clinical management of asthma, COPD, primary ciliary dyskinesia (PCD) and other major lung disease. The article reviews whether current noninvasive measurements of exhaled gases, such as nitric oxide (NO), hydrocarbons, inflammatory markers exhaled breath condensate (EBC) are ready for routine use in clinical practice.
Kharitonov
Sergei A
SA
National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK. s.kharitonov@imperial.ac.uk
D000473:Alkanes / Q000378:metabolism*; D015415:Biomarkers; D001944:Breath Tests; D002908:Chronic Disease; D002925:Ciliary Motility Disorders / Q000378:metabolism; D003371:Cough / Q000378:metabolism; D045853:Exhalation; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism*; D015203:Reproducibility of Results; D012220:Rhinitis / Q000378:metabolism
D000473:Alkanes; D015415:Biomarkers; D009569:Nitric Oxide